Citigroup
SGMO

Citigroup’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Citigroup’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$245K – 5936
2022
Q3 		$245K Buy
50,000
+18,200
+57% +$93.5K ﹤0.01% 3689
2022
Q2 		$132K Buy
+31,800
New +$138K ﹤0.01% 4066
2021
Q1 		– Sell
-162,800
Closed -$2.54M – 7240
2020
Q4 		$2.54M Buy
162,800
+22,600
+16% +$265K ﹤0.01% 2630
2020
Q3 		$1.32M Sell
140,200
-21,700
-13% -$235K ﹤0.01% 3021
2020
Q2 		$1.45M Sell
161,900
-3,300
-2% -$30.6K ﹤0.01% 3160
2020
Q1 		$1.05M Sell
165,200
-21,300
-11% -$158K ﹤0.01% 3121
2019
Q4 		$1.56M Buy
186,500
+84,000
+82% +$772K ﹤0.01% 3270
2019
Q3 		$928K Buy
102,500
+6,900
+7% +$77.4K ﹤0.01% 3725
2019
Q2 		$1.03M Buy
95,600
+34,100
+55% +$363K ﹤0.01% 3593
2019
Q1 		$587K Buy
61,500
+19,000
+45% +$194K ﹤0.01% 4012
2018
Q4 		$488K Sell
42,500
-15,300
-26% -$190K ﹤0.01% 4149
2018
Q3 		$980K Buy
57,800
+2,700
+5% +$41K ﹤0.01% 3527
2018
Q2 		$782K Buy
55,100
+10,700
+24% +$178K ﹤0.01% 3623
2018
Q1 		$844K Buy
44,400
+25,500
+135% +$545K ﹤0.01% 3420
2017
Q4 		$310K Sell
18,900
-8,500
-31% -$126K ﹤0.01% 4613
2017
Q3 		$411K Buy
27,400
+20,800
+315% +$230K ﹤0.01% 4310
2017
Q2 		$58K Buy
6,600
+5,700
+633% +$36.6K ﹤0.01% 5690
2017
Q1 		$5K Sell
900
-100
-10% -$401 ﹤0.01% 6800
2016
Q4 		$3K Buy
+1,000
New +$3.64K ﹤0.01% 7027
2016
Q2 		– Sell
-500
Closed -$3K – 7391
2016
Q1 		$3K Buy
500
+400
+400% +$2.4K ﹤0.01% 7142
2015
Q4 		$1K Sell
100
-1,900
-95% -$14.6K ﹤0.01% 7409
2015
Q3 		$11K Buy
+2,000
New +$16.5K ﹤0.01% 6387

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Citigroup's SGMO Position: Q4 2025 in Review

Citigroup sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 1,369 shares — an estimated $922 sold.

Citigroup first reported a position in SGMO in Q2 2013 and held it in 50 quarters. The position peaked at $5.47M in Q1 2021. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • Citigroup reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 1,369 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $922.
  • Citigroup first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 50 quarters.
  • Citigroup's SANGAMO THERAPEUTICS INC position peaked at $5.47M in Q1 2021.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.